RG-7351

RG-7351 is a trace amine-associated receptor 1 (TAAR1) partial agonist that is or was under development for the treatment of major depressive disorder.^[1][2][3][4] It reached phase 1 clinical trials for this indication in 2010.^[1][2][4] However, as of November 2023, no further recent development has been reported since July 2016.^[1] The drug was developed by Hoffmann-La Roche.^[1][2][4]

RG-7351

Clinical data
Other names	RG7351
Drug class	Trace amine-associated receptor 1 (TAAR1) partial agonist

See also

• Ralmitaront (RG-7906; RO-6889450)
• RG-7410
• Ulotaront (SEP-363856; SEP-856)